Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Days Inventory : 0.00 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Freeline Therapeutics Holdings's Average Total Inventories for the three months ended in Sep. 2023 was $0.00 Mil. Freeline Therapeutics Holdings's Cost of Goods Sold for the three months ended in Sep. 2023 was $0.00 Mil.

The historical rank and industry rank for Freeline Therapeutics Holdings's Days Inventory or its related term are showing as below:

FRLN's Days Inventory is not ranked ^*
in the Biotechnology industry.
Industry Median: 193.86
* Ranked among companies with meaningful Days Inventory only.

Freeline Therapeutics Holdings's Days Inventory stayed the same from Sep. 2022 (0.00) to Sep. 2023 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Freeline Therapeutics Holdings's Inventory-to-Revenue for the three months ended in Sep. 2023 was 0.00.

Freeline Therapeutics Holdings Days Inventory Historical Data

The historical data trend for Freeline Therapeutics Holdings's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Freeline Therapeutics Holdings Days Inventory Chart

Freeline Therapeutics Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Days Inventory

Freeline Therapeutics Holdings Quarterly Data
	Dec18	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Days Inventory	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of Freeline Therapeutics Holdings's Days Inventory

For the Biotechnology subindustry, Freeline Therapeutics Holdings's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Freeline Therapeutics Holdings's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Freeline Therapeutics Holdings's Days Inventory distribution charts can be found below:

* The bar in red indicates where Freeline Therapeutics Holdings's Days Inventory falls into.

Freeline Therapeutics Holdings Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Freeline Therapeutics Holdings's Days Inventory for the fiscal year that ended in Dec. 2022 is calculated as

	Days Inventory (A: Dec. 2022 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2021 )	+	Total Inventories (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Freeline Therapeutics Holdings's Days Inventory for the quarter that ended in Sep. 2023 is calculated as:

	Days Inventory (Q: Sep. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Jun. 2023 )	+	Total Inventories (Q: Sep. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Freeline Therapeutics Holdings (NAS:FRLN) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Freeline Therapeutics Holdings's Inventory Turnover for the three months ended in Sep. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Freeline Therapeutics Holdings's Inventory to Revenue for the three months ended in Sep. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0.005
	=	0.00

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Freeline Therapeutics Holdings Days Inventory Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP

Website

https://www.freeline.life

Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.